KBY Biotech Indexv0.0.34
Search
← Pipeline|AII-IIT-938

AII-IIT-938

Preclinical
By AIIMS New Delhi
Source: Trial-derived·Trials: 1
Modality
Bispecific Ab
MOA
RAS(ON)i
Target
WEE1
Pathway
STING
Dravet
Development Pipeline
Preclinical
Jul 2021
→ Mar 2030
PreclinicalCurrent
NCT03549365
1,729 pts·Dravet
2021-07→2030-03·Completed
1,729 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-184.0y awayInterim· Dravet
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Complet…
Catalysts
Interim
2030-03-18 · 4.0y away
Dravet
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03549365PreclinicalDravetCompleted1729CR
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TAK-2403TakedaPhase 2WEE1BTKi
SovacapivasertibAmgenPhase 3WEE1ALKi
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixaglumideGenmabPhase 2/3WEE1KIF18Ai
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
SovarasimodHalozymePhase 1/2WEE1Anti-Tau
180-3597Innovent BioPreclinicalSHP2RAS(ON)i